Lindbrook Capital LLC Boosts Position in Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Lindbrook Capital LLC lifted its stake in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) by 105.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 238 shares of the company’s stock after acquiring an additional 122 shares during the period. Lindbrook Capital LLC’s holdings in Karuna Therapeutics were worth $75,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of KRTX. Signaturefd LLC raised its holdings in Karuna Therapeutics by 266.7% in the 3rd quarter. Signaturefd LLC now owns 275 shares of the company’s stock valued at $46,000 after buying an additional 200 shares during the period. Exchange Traded Concepts LLC grew its position in Karuna Therapeutics by 34.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 452 shares of the company’s stock valued at $76,000 after acquiring an additional 116 shares in the last quarter. JGP Global Gestao de Recursos Ltda. acquired a new position in Karuna Therapeutics in the 4th quarter valued at about $222,000. China Universal Asset Management Co. Ltd. grew its position in Karuna Therapeutics by 98.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 971 shares of the company’s stock valued at $164,000 after acquiring an additional 481 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC grew its position in Karuna Therapeutics by 5.7% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 1,152 shares of the company’s stock valued at $195,000 after acquiring an additional 62 shares in the last quarter.

Insider Buying and Selling at Karuna Therapeutics

In other Karuna Therapeutics news, insider Stephen K. Brannan sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $318.34, for a total value of $1,591,700.00. Following the completion of the sale, the insider now owns 42,604 shares in the company, valued at $13,562,557.36. The sale was disclosed in a document filed with the SEC, which is available through this link. 13.20% of the stock is owned by company insiders.

Karuna Therapeutics Price Performance

Shares of KRTX opened at $329.83 on Thursday. Karuna Therapeutics, Inc. has a 52-week low of $158.38 and a 52-week high of $329.99. The stock has a 50 day moving average price of $325.22 and a 200 day moving average price of $269.92. The company has a market capitalization of $12.58 billion, a price-to-earnings ratio of -28.14 and a beta of 1.18.

Karuna Therapeutics (NASDAQ:KRTX) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($3.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.65) by ($0.36). During the same quarter in the prior year, the firm posted ($2.22) earnings per share. The company’s quarterly revenue was down 100.0% on a year-over-year basis. On average, equities analysts anticipate that Karuna Therapeutics, Inc. will post -11.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on KRTX shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $330.00 target price (up from $217.00) on shares of Karuna Therapeutics in a research report on Thursday, December 28th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $330.00 target price on shares of Karuna Therapeutics in a research report on Tuesday, February 20th. HC Wainwright reissued a “neutral” rating and set a $330.00 price objective on shares of Karuna Therapeutics in a research report on Thursday, March 14th. Finally, Mizuho reissued a “neutral” rating and set a $330.00 price objective (up from $245.00) on shares of Karuna Therapeutics in a research report on Friday, January 26th. Ten equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $293.92.

Karuna Therapeutics Company Profile

Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease.